Table 1.

Clinical trials of combined radiotherapy, DDR inhibitors, and ICIs

Trial ID	Phase	Tumor type	RT type	DDRi		ICI
NCT04550104	Phase 1	NSCLC	RT	Ceralasertib AZD1390 Olaparib Saruparib	ATRi ATMi PARPi	Durvalumab
NCT04068194	Phase 1/2	Cholangiocarcinoma Gallbladder Carcinoma	HFRT	Peposertib	DNA-PKi	Avelumab
NCT04711824	Phase 1/2	Breast cancer	SRS	Olaparib	PARPi	Durvalumab
NCT05568550	Phase 2	Prostate Cancer	RT	Olaparib	PARPi	Pembrolizumab
NCT05379972	Phase 2	Gastric Cancer GastroEsophageal Cancer	SBRT	Olaparib	PARPi	Pembrolizumab
NCT06074692	Phase 2	Sarcoma	SBRT	Fluzoparib	PARPi	Camrelizumab
NCT05568550	Phase 2	Prostate Cancer	RT	Olaparib	PARPi	Pembrolizumab
NCT05366166	Phase 2	HNSCC	IMRT	Olaparib	PARPi	Pembrolizumab
NCT04380636	Phase 3	NSCLC	RT	Olaparib	PARPi	Pembrolizumab
NCT04624204	Phase 3	LS-SCLC	RT	Olaparib	PARPi	Pembrolizumab
NCT05411094	Phase 1	Pancreatic Cancer	RT	Olaparib	PARPi	Durvalumab
NCT04728230	Phase1/2	ES-SCLC	RT	Olaparib	PARPi	Durvalumab
NCT06197581	Not Applicable	Breast Cancer	RT	Olaparib	PARPi	Pembrolizumab
NCT04683679	Phase 2	Breast Cancer	SBRT	Olaparib	PARPi	Pembrolizumab
NCT04837209	Phase 2	Breast Cancer	RT	Niraparib	PARPi	Dostarlimab
NCT04681469	Phase 3	Prostate Cancer	RT	Olaparib	PARPi	Pembrolizumab
NCT03834519	Phase 3	Prostate Cancer	EBRT	Olaparib	PARPi	Pembrolizumab
NCT03307785	Phase 1	NSCLC	RT	Niraparib	PARPi	Dostarlimab

Note: Full access to the research studies description is available on ClinicalTrials.gov

Abbreviations: NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; LS-SCLC, limited-stage small-cell lung cancer; ES-SCLC, extensive-stage small-cell lung cancer; RT, radiotherapy; HFRT, hypofractionated radiotherapy; SBS, stereotactic radiosurgery; SBRT, stereotactic body radiation therapy; IMRT, intensity modulated radiotherapy; EBRT, external-beam radiation therapy